Entering text into the input field will update the search result below

Asterias Bio's study of AST-OPC1 in acute spinal cord injury to continue; shares ahead 10%

  • Asterias Biotherapeutics (NYSEMKT:AST) is up 10% on double normal volume in response to its announcement that, based on the recommendation from the Data Monitoring Committee, its Phase 1/2a clinical trial, SCiStar, assessing AST-OPC1 in acute spinal injury will continue as planned without modification.
  • According to ClinicalTrials.gov, the estimated study completion date is September 2018. The enrollment target is 35 subjects.

Recommended For You

Related Stocks

SymbolLast Price% Chg
AST--
Asterias Biotherapeutics, Inc.